Skip to content
HomeLatest newsWhat you need to know about Johnson & Johnson’s 2017 second-quarter earnings
J&J Building Flag Summer

What you need to know about Johnson & Johnson’s 2017 second-quarter earnings

Check out this infographic breakdown of the company’s second-quarter 2017 performance, with key highlights from its consumer, pharmaceutical and medical devices businesses.

Johnson & Johnson shared financial information this morning about its second-quarter performance in 2017.

Since its founding in 1886, the company has grown to become one of the world’s largest and most broadly based healthcare companies, with approximately 135,000 employees across the globe working every day to help change the trajectory of health for humanity.

For more details about the company’s second-quarter 2017 results, and to read a message from Chairman and Chief Executive Officer Alex Gorsky, here’s an infographic packed with key stats.

2017 Second Quarter Earnings

Johnson & Johnson’s 2017 2nd-Quarter Earnings

Read the earnings press release, which includes full financial data for the second quarter of the year.

Want to see more company earnings information? Find several years of Johnson & Johnson quarterly and full-year results here.

More from Johnson & Johnson

How Johnson & Johnson is fighting medical counterfeiting

Fake medication and compromised devices are part of a global market that poses a significant threat to the health of patients. Here’s how the company’s Global Brand Protection team helps keep people safe.

What are cataracts?

If you can’t read a screen without jacking up the brightness level or if night driving leaves you seeing fuzzy halos around traffic lights, you may among the 20 million U.S. adults who develops a cataract—the most common cause of vision loss worldwide. Luckily a simple surgical procedure can have you viewing the world in crisp, bright color again. Here’s what to know about cataract symptoms and removal.

Meet two brothers who are revolutionizing the way scientists develop treatments for cancer

Justin and Colin Farlow share how their next-generation cell and gene therapies are helping Johnson & Johnson in its quest to get in front of cancer.